Abiopharma

Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: Disclosure of Interest/ Change in Interest of Director

Share Buy Back - Daily Share Buy-Back Notice: Daily Share Buy-Back Notice

DHT Holdings, Inc. announces the results of the 2026 annual meeting of shareholders

Mandatory Cash Dividend/ Distribution:

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: Disclosure of Interest/ Change in Interest of Director

MOGU Announces Unaudited Financial Results for the Six Months Ended March 31, 2026 and Fiscal Year 2026

CFO Departure Announcement

Ennis, Inc. Reports Results for the Quarter Ended May 31, 2026 and Declares Quarterly Dividend